Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

  • End date
    Oct 15, 2025
  • participants needed
  • sponsor
    Boston Scientific Corporation
Updated on 13 June 2021
Jacqueline Beaulieu
Primary Contact
Kyoto University Hospital (1.4 mi away) Contact
+241 other location


The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for ICD therapy and programmed according to current guidance of higher rate cut-offs and therapy delays. The time to first all-cause shock will be tested in subjects with standard therapy (ATP and shocks) compared to subjects programmed to shock only to assess equivalency.

Condition Sudden Cardiac Death
Treatment Arm 1 (ATP+Shock), Arm 2 (shock only)
Clinical Study IdentifierNCT02923726
SponsorBoston Scientific Corporation
Last Modified on13 June 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note